FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group

Hofheinz, Ralf‐Dieter; Merx, Kirsten; Martin Haag, Georg; Springfeld, Christoph; J. Ettrich, Thomas; Borchert, K; Kretzschmar, Albrecht; Teschendorf, Christian; Margareta Siegler, Gabriele; P. Ebert, Matthias; Goekkurt, Eray; Mahlberg, Rolf; Homann, Nils; Pink, Daniel; O. Bechstein, Wolf; Reichardt, Peter; Zwenneke Flach, H.; Gaiser, Timo; Battmann, A.; Oduncu, Fuat; Loose, Maria; Sookthai, Disorn; Pauligk, Claudia; Oliver Goetze, Thorsten; Al‐Batran, Salah‐Eddin

doi:10.1200/jco.22.00380

Public

FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group

Published in Journal of Clinical Oncology • Jun 16, 2022

Authors:

Ralf‐Dieter Hofheinz

Kirsten Merx

Georg Martin Haag

Abstract

PURPOSE High pathologic complete response (pCR) rates and comparably good survival data were seen in a phase II trial combining perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy with trastuzumab for resectable, esophagogastric adenocarcinoma (EGA). The current tr...

Subject

Pertuzumab

Medicine

Trastuzumab

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!